[Uricosuric agent].
Urate lowering treatment is indicated in patients with recurrent acute attacks, tophi, gouty arthropathy, radiographic changes of gout, multiple joint involvement, or associated uric acid nephrolithiasis. Uricosuric agents like benzbromarone and probenecid are very useful to treat hyperuricemia as well as allopurinol (xanthine oxidase inhibitor). Uricosuric agents act the urate lowering effect through blocking the URAT1, an urate transporter, in brush border of renal proximal tubular cells. In order to avoid the nephrotoxicity and urolithiasis due to increasing of urinary urate excretion by using uricosuric agents, the proper urinary tract management (enough urine volume and correction of aciduria) should be performed.
Ohno
Iwao
I
Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine.
D000493:Allopurinol / Q000008:administration & dosage / Q000494:pharmacology; D001553:Benzbromarone / Q000008:administration & dosage / Q000494:pharmacology; D006073:Gout / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D033461:Hyperuricemia / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D007687:Kidney Tubules, Proximal / Q000378:metabolism; D027361:Organic Anion Transporters / Q000037:antagonists & inhibitors; D027701:Organic Cation Transport Proteins / Q000037:antagonists & inhibitors; D014527:Uric Acid / Q000378:metabolism; D014528:Uricosuric Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
D027361:Organic Anion Transporters; D027701:Organic Cation Transport Proteins; C491241:SLC22A12 protein, human; D014528:Uricosuric Agents; D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol